ClinicalTrials.gg
RecruitingNCT07233499Updated Nov 19, 2025

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

A Phase 2 interventional study of Nebivolol 5 mg in HER2-positive Breast Cancer, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Ain Shams University · Phase 2, Interventional, and Prevention

How we know · 3 judgments

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2025, registered Nov 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Breast Neoplasms by Ain Shams University — 9 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Ain Shams University.

Planned enrollment
10th of 12
56 · median 80
Started
2025
with 1 other
Phase 2
4 of 26
3 open now
Registered
24th of 26
by date

Among the 26 studies in Breast Neoplasms by Ain Shams University, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 24th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 26 studies in Breast Neoplasms by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by Ain Shams University, or all of them as a file.
02

Study summary

Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER2). Previously patients who were diagnosed with HER2 positive breast cancer were considered of poor survival but after the discovery of trastuzumab, disease free survival among these patients was improved significantly.

Though trastuzumab has made great improvement in the treatment of breast cancer, it was identified to possess a major side effect which is cardiotoxicity . Cardiotoxicity that occurs with anticancer agents is usually manifested as left ventricular dysfunction (LVD) and overt heart failure (HF). LVD was defined as a decrease in cardiac LV ejection fraction (LVEF), that is either global or more severe in the septum, symptoms of congestive heart failure (CHF), associated signs of CHF including but not limited to S3 gallop, tachycardia or both and decline in LVEF of at least 5% to below 55% with accompanying signs or symptoms of CHF, or a decline in LVEF of at least 10% to below 55% without accompanying signs or symptoms.

Beta blockers have shown a cardioprotective effect against chemotherapy induced- cardiotoxicity.

Nebivolol is a third-generation beta blocker. It is highly selective to B1- adrenergic receptors. It also has peripheral vasodilating effect due to its effect on L-arginine/ nitric oxide pathway in the endothelium of blood vessels.

The dose of nebivolol given in the study was 5mg/day for the entire period of the study. Echo was done for all patients to determine the changes of left ventricular ejection fraction in patients in the treatment group and control group. The study concluded that nebivolol prevented the occurrence of anthracycline induced cardiotoxicity.

the current study will be the first clinical trial to evaluate the cardioprotective effect of nebivolol on trastuzumab-induced cardiotoxicity in breast cancer patients.

Aim of the work

Evaluation of the effect of Nebivolol on trastuzumab - induced cardiotoxicity in non-metastatic breast cancer patients by assessment of:

  • Left ventricular ejection fraction.
  • Cardiac biomarkers (troponin- Pro- BNP).
  • Treatment safety.
  • Patient quality of life (Using fact-B questionnaire)
Read the detailed description

Breast cancer is one of the most common malignancies that affect females around the world. According to the WHO, the number of females who were diagnosed with breast cancer in 2020 in Egypt was 22038 females. This number represents 32.4% of all women malignancies and 16.4% of all malignancies in Egypt (men and women).

Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER2). Previously patients who were diagnosed with HER2 positive breast cancer were considered of poor survival but after the discovery of trastuzumab, disease free survival among these patients was improved significantly.

Trastuzumab is a humanized monoclonal antibody that was approved to treat HER2 positive breast cancer. Studies have shown that trastuzumab has improved the survival, reduced the mortality, reduced the recurrence and metastases rates in patients with HER2 positive breast cancer. Trastuzumab perform its tumor suppressive actions through different mechanisms that include activation of antibody-dependent cell-mediated cytotoxicity, inhibition of HER2 extracellular domain cleavage, disruption of HER2 receptor homodimerization and heterodimerization, abrogation of oncogenic cellular signaling and downregulation of angiogenesis and DNA repair pathways.

Though trastuzumab has made great improvement in the treatment of breast cancer, it was identified to possess a major side effect which is cardiotoxicity. Cardiotoxicity that occurs with anticancer agents is usually manifested as left ventricular dysfunction (LVD) and overt heart failure (HF). LVD was defined as a decrease in cardiac LV ejection fraction (LVEF), that is either global or more severe in the septum, symptoms of congestive heart failure (CHF), associated signs of CHF including but not limited to S3 gallop, tachycardia or both and decline in LVEF of at least 5% to below 55% with accompanying signs or symptoms of CHF, or a decline in LVEF of at least 10% to below 55% without accompanying signs or symptoms.

According to a study conducted by Mohan et al in 2016, It was shown that treatment with trastuzumab leads to inhibition of HER2 signaling and phosphorylation of HER1-Y845/HER2-Y1248 and the activation of Erk. All this consequently leads to upregulation of the mTOR-Ulk1 pathway to mediate inhibition of autophagy in cardiomyocytes. This was clearly shown by the decrease in expression levels of LC3 I/II and increase in p62 after trastuzumab treatment. Studies has shown that inhibition of autophagy by autophagy inhibitor (3-methyladenine) leads to accumulation of damaged mitochondria and increase the concentration of mitochondrial ROS and thus accumulation of toxic reactive oxygen species (ROS) in human cardiomyocytes which can lead to oxidative damage and cardiotoxicity.

Beta blockers have been used to treat ischemic heart disease due to their negative chronotropic and inotropic properties thus inducing a decrease in myocardial consumption of oxygen and nutrients allowing better balance between nutritional needs and blood flow. Recent studies have proved that not all beta blockers have equal effect as their intercellular mechanisms of action are different. Beta blockers have shown a cardioprotective effect against chemotherapy induced- cardiotoxicity.

Nebivolol is a third-generation beta blocker. It is highly selective to B1- adrenergic receptors. It also has peripheral vasodilating effect due to its effect on L-arginine/ nitric oxide pathway in the endothelium of blood vessels. Nitric oxide is a paracrine factor derived from the endothelial cells and alleviate ROS mediated oxidative damage. Nebivolol activates the endothelial nitric oxide system and increases nitric oxide release through activation of the beta 3 adrenergic receptors in endothelium cells. The release of nitric oxide causes peripheral vasodilation, an increase in the myocardial compliance and an inhibition of inotropic effect of sympathetic stimulation. Nebivolol also decreases the nitric oxide break down and increases its bioavailability. All these effects of nebivolol on nitric oxide lead to a decrease in cardiac load, an enhanced cardiac filling and a protection of myocardium.

In a meta-analysis of 12 clinical trials, it was found that there was a great decrease in reactive oxygen species (ROS) concentration in endothelial cells exposed to oxidative stress in patients who were taking nebivolol in comparison to other patients who were receiving other beta blockers. Besides, it was found that the decrease of basal and stimulated nitric oxide because of oxidative stress is less in patients taking nebivolol compared to other patients. This all shows that nebivolol has antioxidant properties which reduce oxidative stress and affects organs damage.

The animal study which is conducted in 2018 to assess the Protective effect of nebivolol on doxorubicin-induced cardiotoxicity in rats. The specimens were examined using H + E and Masson's trichrome, caspase 3, endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS) and tumor necrosis factor factor-α (TNF-α). The mean area percentage of collagen fiber content, caspase-3, eNOS, iNOS and TNF-α immunoactivities was measured. Doxorubicin-treated group showed marked myocyte distortion and fragmentation, congestion and cytoplasmic lysis in most fibers. These changes were less intense in the nebivolol-treated group. The study concluded that nebivolol exerted a significant protective effect from doxorubicin toxicity. The protective effect appears to be mediated mainly through caspase-3, eNOS, iNOS and TNF-α modulation.

Cochera and his colleagues conducted a study in 2018 to assess the effect of nebivolol treatment in the prevention of anthracyclines induced cardiotoxicity. The dose of nebivolol given in the study was 5mg/day for the entire period of the study. Echo was done for all patients to determine the changes of left ventricular ejection fraction in patients in the treatment group and control group. The study concluded that nebivolol prevented the occurrence of anthracycline induced cardiotoxicity.

the current study will be the first clinical trial to evaluate the cardioprotective effect of nebivolol on trastuzumab-induced cardiotoxicity in breast cancer patients.

Aim of the work

Evaluation of the effect of Nebivolol on trastuzumab - induced cardiotoxicity in non-metastatic breast cancer patients by assessment of:

  • Left ventricular ejection fraction.
  • Cardiac biomarkers (troponin- Pro- BNP).
  • Treatment safety.
  • Patient quality of life (Using fact-B questionnaire)
03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • Nebivolol
  • trastuzumab
  • HER-2 positive
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old.
  • Newly diagnosed with early or locally advanced positive breast cancer.
  • Normal baseline (˃50%)
  • Planned to receive HER2-directed therapies as newadjuvant or adjuvant.

Exclusion criteria

Exclusion Criteria:

  • Elderly patients( ˃65 years).

    • Primary tumors other than breast cancer.
    • Pregnancy and breast feeding.
    • Currently using cardioprotective drugs e.g.: ACEI, CCB, ARBs and another beta blocker.
    • Presence of diagnosed cardiomyopathy currently or in initial evaluation.
    • Patients with ischemic heart disease.
    • for treatment with beta blockers.
    • Patients with to nebivolol.
    • Poorly echogenic patients.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Nebivolol

    Nebivolol group (28 patients): will receive nebivolol at a dose of 5 mg once daily (orally) during the whole period of receiving trastuzumab

    Drug: Nebivolol 5 mg

  • No intervention
    Control group

    Control group (28 patients): will receive no intervention during the trastuzumab therapy

Interventions

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Measurement of Left ventricular ejection fraction by Echocardiography

    Echo will be done at baseline (before start of trastuzumab) and every 3 months during receiving trastuzumab to evaluate the reduction in the left ventricular ejection fraction and overall cardiac function

    Time frame: 12 months

Secondary outcomes

  1. II-Evaluation of cardiac biomarkers.

    Serum and plasma samples will be withdrawn from every patient at baseline, before surgery , after surgery and at the end of the study. Serum samples for evaluation of troponin and plasma samples for evaluation of pro-BNP. The samples will be stored at -20 till analysis.

    Time frame: 12 months

  2. Number of participants with treatment-related adverse events

    Patients 'blood samples will be taken at baseline, 6 months and 12 months to check their liver functions, kidney functions and CBC. Nebivolol side effects will be followed up during regular phone calls with the patients every two weeks. the number of participants with adverse events will be recorded

    Time frame: 12 months.

  3. Evaluation of Quality of Life.

    ● The quality of life will be assed using Functional assessment of cancer therapy-Breast (FACT-B) at baseline, after 6 months and at the end of the study. the questionnaire assesses functional, social , physical and emotional well being. The score ranges from 0-148 with higher scores indicating better quality of life

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 25 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 18, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07233499
Responsible party
May Ahmed Shawki (Associate professor, Ain Shams University) — Principal investigator
First posted
Nov 18, 2025
Start date
Jan 1, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Nov 19, 2025

Study contacts

May A Shawki, Ph.D
Contact
mayahmed@pharma.asu.edu.eg
01001701461

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nebivolol

Start the discussion